Ceftazidime-Avibactam Dosing for CKD Stage 3b
For patients with CKD stage 3b (creatinine clearance 30-44 mL/min), administer ceftazidime-avibactam 1.25 g (ceftazidime 1 g/avibactam 0.25 g) IV every 12 hours, infused over 2 hours.
Dosing Algorithm by Renal Function
The FDA-approved dosing for ceftazidime-avibactam requires adjustment based on estimated creatinine clearance 1:
Standard Dosing Framework:
- CrCl >50 mL/min: 2.5 g (2 g/0.5 g) IV every 8 hours
- CrCl 31-50 mL/min (CKD 3b): 1.25 g (1 g/0.25 g) IV every 12 hours
- CrCl 16-30 mL/min: 0.94 g (0.75 g/0.19 g) IV every 24 hours
- CrCl 6-15 mL/min: 0.94 g (0.75 g/0.19 g) IV every 48 hours
- CrCl <5 mL/min or hemodialysis: Specific post-dialysis dosing required
Infusion Duration
Administer as a 2-hour infusion for all renal function categories 1. Recent evidence suggests that extending infusion time to 3 hours may optimize pharmacodynamic target attainment in severe infections, particularly for patients with preserved renal function 2, but the standard 2-hour infusion remains appropriate for CKD 3b patients.
Pharmacokinetic Rationale
Both ceftazidime and avibactam are eliminated almost exclusively by the kidneys through glomerular filtration 1. In CKD 3b:
- Clearance is significantly reduced: Total body clearance correlates linearly with creatinine clearance (R = 0.91 for ceftazidime, R = 0.88 for avibactam) 3
- Half-life is prolonged: Approximately doubles compared to normal renal function
- Drug accumulation risk: Without dose adjustment, steady-state concentrations can exceed therapeutic targets and approach neurotoxicity thresholds
Pharmacodynamic Targets
The recommended dosing achieves appropriate PK/PD targets 3, 2:
- Ceftazidime: ≥50% fT>MIC (percentage of dosing interval that free drug concentration exceeds the MIC)
- Avibactam: ≥50% fT>1 mg/L (threshold concentration to inhibit β-lactamases)
For CKD 3b patients, the 1.25 g every 12 hours regimen maintains adequate exposure without excessive accumulation 4.
Critical Monitoring Parameters
Renal Function Assessment
Calculate creatinine clearance using the Cockcroft-Gault equation 1:
Males: CrCl (mL/min) = [Weight (kg) × (140 - age)] / [72 × serum creatinine (mg/dL)]
Females: 0.85 × male value
Safety Monitoring
Monitor for neurotoxicity risk, particularly if:
- Serum creatinine fluctuates significantly
- Patient develops acute kidney injury
- Ceftazidime trough concentrations exceed 80-104 mg/L 5, 6
Common pitfall: Failing to reassess renal function during treatment. CKD 3b patients may experience further renal decline or improvement, necessitating dose adjustment.
Special Considerations
Augmented Renal Clearance
If the patient paradoxically has augmented clearance (uncommon in CKD 3b but possible in younger patients with acute processes), standard dosing may be insufficient 7. Consider therapeutic drug monitoring if clinical response is suboptimal.
Hemodialysis Transition
If the patient progresses to requiring hemodialysis, switch to post-dialysis dosing: loading dose of 2.5 g, then 0.94 g after each dialysis session 1, 8.
Continuous Renal Replacement Therapy (CRRT)
If CRRT is initiated, standard dosing often results in excessive drug exposure 6. Dose reduction and therapeutic drug monitoring become essential to prevent neurotoxicity.
Loading Dose
No loading dose is required for CKD 3b patients when using the adjusted maintenance regimen 1. Loading doses are reserved for patients with normal renal function or specific clinical scenarios requiring rapid attainment of therapeutic concentrations.
Duration of Therapy
Continue treatment for 2 days after clinical signs and symptoms of infection resolve, though complicated infections may require longer courses 1. The dosing interval of every 12 hours in CKD 3b provides sustained coverage throughout the treatment period.